login
login
Image header Agence Europe
Europe Daily Bulletin No. 13717
SECTORAL POLICIES / Health

EU authorises drug to combat early stages of Alzheimer’s disease

On Thursday 25 September, the European Commission announced that it had granted marketing authorisation for Kisunla (donanemab), a drug designed to treat mild cognitive impairment, including mild dementia in the early stages of Alzheimer’s disease.

Kisunla was developed by the pharmaceutical company Eli Lilly and Company. Kisunla is a monoclonal antibody administered by intravenous infusion.

According to the Commission, Kisunla may help to “slow down the progression of cognitive and...

Contents

SECTORAL POLICIES
ECONOMY - FINANCE - BUSINESS
Russian invasion of Ukraine
SECURITY - DEFENCE
EXTERNAL ACTION
INSTITUTIONAL
SOCIAL AFFAIRS - EMPLOYMENT
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
EDUCATION - YOUTH - CULTURE - SPORT
NEWS BRIEFS